RecruitingPhase 2NCT06536868

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Tislelizumab Plus Chemotherapy and Concurrent Thoracic Radiotherapy as First-line Therapy for Extensive-stage Small-Cell Lung Cancer (ES-SCLC): an Multicenter, Single Arm Prospective Trial

Sponsor

Second Hospital of Shanxi Medical University

Enrollment

40 participants

Start Date

Aug 1, 2024

Study Type

INTERVENTIONAL

Conditions

Extensive-stage Small-cell Lung Cancer

Summary

This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria8

Patients aged between 18 to 80 years old (inclusive of 18th and 80th birthdays), male or female, at the time of signing the informed consent form;
Confirmed small cell lung cancer of extensive stage by histology or cytology;
At least one measurable lesion by imaging studies (according to RECIST 1.1) with a long diameter of ≥10 mm as examined by spiral CT or MRI;
Within 3 days prior to treatment, an ECOG score of 0 to 1;
No prior antitumor treatment for extensive stage disease (if the patient has previously received chemotherapy and/or radiotherapy in the limited stage of SCLC, the treatment intent must have been curative, and there must be at least a 6-month treatment-free interval between the end of chemotherapy, radiotherapy, or chemoradiotherapy and the diagnosis of extensive stage SCLC);
Expected life span of ≥3 months;
Good function of vital organs;
The subject voluntarily joins this study, signs the informed consent form, has good compliance, and cooperates with follow-up.

Exclusion Criteria6

Concurrent severe respiratory diseases: such as pulmonary fibrosis;
Presence of psychiatric disorders, hematologic diseases, autoimmune diseases, and severe primary diseases of the heart, brain, liver, or kidneys;
Uncontrolled active infections;
Known or suspected allergies to the study medication and its excipients;
Female patients who are pregnant or breastfeeding, or women of childbearing potential with a positive baseline pregnancy test;
Prior use of antitumor treatment targeting the PD-(L)1 pathway.

Interventions

DRUGTislelizumab

Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).

DRUGEtoposide

Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).

DRUGCarboplatin or Cisplatin

Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).

RADIATIONThoracic radiotherapy

IMRT 30-45Gy/10-15f